Anti-Rheumatic Drugs - Indonesia

Indonesia

The Anti-Rheumatic Drugs market in Indonesia is expected to witness a significant growth in revenue.
By 2024, the projected revenue is estimated to reach US$86.68m.
This growth is anticipated to continue, with an annual growth rate (CAGR 2024-2028) of 1.35%.
As a result, the market volume is projected to reach US$91.47m by 2028.
In global comparison, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, the revenue generated United States is projected to be US$37,550.00m.
In Indonesia, the demand for anti-rheumatic drugs is on the rise due to an aging population and increasing prevalence of rheumatoid arthritis.

Key regions: France, Italy, Brazil, China, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Indonesia has been showing an upward trend in recent years.

Customer preferences: Customers in Indonesia are becoming more aware of the benefits of Anti-Rheumatic Drugs. The increasing prevalence of rheumatic diseases in the country has led to a rise in demand for these drugs. Patients are also becoming more inclined towards biologic drugs due to their effectiveness in treating rheumatic diseases.

Trends in the market: The Indonesian government has been taking steps to improve the healthcare sector in the country, which has led to an increase in the availability of Anti-Rheumatic Drugs. The market has also seen the entry of new players, leading to increased competition. This has resulted in a decrease in the prices of these drugs, making them more affordable for patients.

Local special circumstances: Indonesia has a large population, and the prevalence of rheumatic diseases is high in the country. The lack of awareness about these diseases has led to a delay in diagnosis and treatment, which has further increased the demand for Anti-Rheumatic Drugs. The country also has a large number of traditional medicine practitioners who play a significant role in the treatment of rheumatic diseases.

Underlying macroeconomic factors: The Indonesian economy has been growing steadily in recent years, which has led to an increase in the purchasing power of consumers. This has resulted in a rise in demand for healthcare services, including Anti-Rheumatic Drugs. The government has also been investing in the healthcare sector, which has led to an increase in the availability of these drugs.In conclusion, the Anti-Rheumatic Drugs market in Indonesia has been growing steadily due to the increasing prevalence of rheumatic diseases, the entry of new players, and the government's efforts to improve the healthcare sector. The market is expected to continue to grow in the coming years due to the rising awareness about these diseases and the increasing availability of these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.